Перейти к содержимому страницы
pepts.wiki

Мы не врачи, и ничто здесь не является медицинской консультацией. Всегда сначала проконсультируйтесь с медицинским специалистом. Почему мы так говорим

Машинный перевод с английского, который является эталонным. Читать на английском

Питательное вещество или кофакторStub

NAD+

Кофермент (не пептид)

Никотинамидадениндинуклеотид, кофермент энергетического обмена в каждой клетке. Это не пептид.

Кратко

Питательное вещество или кофактор

Витамин, аминокислота или кофактор. Указан, поскольку продаётся отдельно и в смесях.

Эта страница является заглушкой

The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.

NAD+: в PubMed

What PubMed held for NAD+ on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.

1,088
papers
526
in humans
19
clinical trials
12
randomized trials
2012: 14 papers122013: 25 papers2014: 32 papers142015: 17 papers2016: 36 papers162017: 36 papers2018: 63 papers182019: 58 papers2020: 68 papers202021: 76 papers2022: 82 papers222023: 91 papers2024: 112 papers242025: 125 papers2026: 139 papers so far26
Papers per year, 2012 to 2026. The most in one year: 139.

Most relevant on PubMed

Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.

  1. Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review

    ReviewGindri IM, Ferrari G, Pinto LPS, et al. American journal of physiology. Endocrinology and metabolism, 2024. PMID 37971292

  2. Supplementation with NAD+ Precursors for Treating Alzheimer's Disease: A Metabolic Approach

    ReviewAlghamdi M, Braidy N Journal of Alzheimer's disease : JAD, 2024. PMID 39422945

  3. NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence

    ReviewGallagher C, Emmanuel OO Ageing research reviews, 2026. PMID 41655607

  4. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD(+) in healthy middle-aged and older adults

    Randomized trialMartens CR, Denman BA, Mazzo MR, et al. Nature communications, 2018. PMID 29599478

  5. Boosting NAD level suppresses inflammatory activation of PBMCs in heart failure

    TrialZhou B, Wang DD, Qiu Y, et al. The Journal of clinical investigation, 2020. PMID 32790648

  6. Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD(+) Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures

    Randomized trialElhassan YS, Kluckova K, Fletcher RS, et al. Cell reports, 2019. PMID 31412242

  7. NAD+ and sirtuins in aging and disease

    ReviewImai S, Guarente L Trends in cell biology, 2014. PMID 24786309

  8. NAD⁺ in aging, metabolism, and neurodegeneration

    ReviewVerdin E Science (New York, N.Y.), 2015. PMID 26785480

Search used: ("NAD+"[ti] AND (supplementation[tiab] OR precursor[tiab] OR aging[tiab])). Run it on PubMed

Исследовательские ссылки

Also in Skin and longevity

Sold in blends: 5-Amino-1MQ + NAD+